Alzheimer Disease Blood Test May Have Higher Rate of False Positives Than Expected

The Testosterone Therapy Debate

JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Testosterone Therapy: Does New Evidence Warrant Broader Prescribing?" Related Content: * Testosterone Therapy: Does New Evidence Warrant Broader Prescribing? [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.13149?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

Alzheimer Disease Blood Test May Have Higher Rate of False Positives Than Expected

JAMA Medical News Associate Managing Editor Kate Schweitzer and Lead Senior Staff Writer Rita Rubin discuss "First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds." Related Content: * First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.12326?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

PMOS is the New PCOS

JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "PCOS is Now PMOS—Will a New Name Translate to Improved Clinical Care?" Related Content: * PCOS Is Now PMOS—Will a New Name Translate to Improved Clinical Care? [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10402?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content: * A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026 [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7591?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

Why Exercise Still Matters in the GLP-1 Drug Era

JAMA Medical News Director Jennifer Abbasi and Staff Writer Samantha Anderer discuss "In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA." Related Content: * In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.11338?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]